My first post-earnings play of the season is BLUD. Immucor surpassed expectations Thursday and is now consolidating it’s big high volume spike. OBV looks good and there’s a nice volume pattern forming.
I bought 400 shares at $38.25.
Update: I bought 40 shares of BIDU at $321.23. Pullback is a bit harsh, but I’m guessing it’s an overreaction to JP Morgan comments. My stop is at $310, making this a low risk speculative play.